Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial von Albiges, Laurence, Tannir, Nizar M, Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K, Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Choueiri, Toni K, Saggi, Shruti Shally, McHenry, M Brent, Motzer, Robert J

Volltext

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random... von Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M

Volltext

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy von Choueiri, Toni K, Kluger, Harriet, George, Saby, Tykodi, Scott S, Kuzel, Timothy M, Perets, Ruth, Nair, Suresh, Procopio, Giuseppe, Carducci, Michael A, Castonguay, Vincent, Folefac, Edmund, Lee, Chung-Han, Hotte, Sebastien J., Miller, Wilson H, Saggi, Shruti Shally, Lee, Chung-Wei, Desilva, Heshani, Bhagavatheeswaran, Prabhu, Motzer, Robert J, Escudier, Bernard

Volltext

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma von Tannir, Nizar M., Signoretti, Sabina, Choueiri, Toni K., McDermott, David F., Motzer, Robert J., Flaifel, Abdallah, Pignon, Jean-Christophe, Ficial, Miriam, Frontera, Osvaldo Aren, George, Saby, Powles, Thomas, Donskov, Frede, Harrison, Michael R., Barthelemy, Philippe, Tykodi, Scott S., Kocsis, Judit, Ravaud, Alain, Rodriguez-Cid, Jeronimo R., Pal, Sumanta K., Murad, Andre M., Ishii, Yuko, Saggi, Shruti Shally, McHenry, M. Brent, Rini, Brian

Volltext

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial... von Motzer, Robert J., Escudier, Bernard, George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Plimack, Elizabeth R., Procopio, Giuseppe, McDermott, David F., Castellano, Daniel, Choueiri, Toni K., Donskov, Frede, Gurney, Howard, Oudard, Stéphane, Richardet, Martin, Peltola, Katriina, Alva, Ajjai S., Carducci, Michael, Wagstaff, John, Chevreau, Christine, Fukasawa, Satoshi, Tomita, Yoshihiko, Gauler, Thomas C., Kollmannsberger, Christian K., Schutz, Fabio A., Larkin, James, Cella, David, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.

Volltext

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial von Albiges, Laurence, Tannir, Nizar M., Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R., Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K., Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I., Choueiri, Toni K., Leung, David, Saggi, Shruti Shally, Lee, Chung-Wei, McHenry, M. Brent, Motzer, Robert J.

Volltext

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC) von Motzer, Robert J., Tykodi, Scott S., Escudier, Bernard, Oudard, Stephane, Hammers, Hans J., McDermott, David F., George, Saby, Castellano, Daniel, Choueiri, Toni K., Alva, Ajjai Shivaram, Richardet, Martin Eduardo, Plimack, Elizabeth R., Srinivas, Sandy, Procopio, Giuseppe, Donskov, Frede, Gurney, Howard, Tomita, Yoshihiko, McHenry, M. Brent, Saggi, Shruti Shally, Tannir, Nizar M.

Volltext

Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with ad... von Tannir, Nizar M., McDermott, David F., Escudier, Bernard, Hammers, Hans J., Aren, Osvaldo Rudy, Plimack, Elizabeth R., Barthelemy, Philippe, Neiman, Victoria, George, Saby, Porta, Camillo, Powles, Thomas, Donskov, Frede, Grimm, Marc-Oliver, Amin, Asim, Tykodi, Scott S., Tomita, Yoshihiko, Rini, Brian I., McHenry, M. Brent, Saggi, Shruti Shally, Motzer, Robert J.

Volltext